SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:bfc60449-4e98-49ea-bd8e-dfd7f76ada78"
 

Search: onr:"swepub:oai:lup.lub.lu.se:bfc60449-4e98-49ea-bd8e-dfd7f76ada78" > Transcriptomic anal...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma

Thakur, Rohit (author)
University of Leeds,University of Texas
Laye, Jonathan P. (author)
University of Leeds
Lauss, Martin (author)
Lund University,Lunds universitet,Melanoma Genomics,Forskargrupper vid Lunds universitet,Lund University Research Groups
show more...
Diaz, Joey Mark S. (author)
University of Leeds
O'Shea, Sally Jane (author)
Mater Private Hospital Cork,University College Cork
Pozniak, Joanna (author)
Catholic University of Leuven,University of Leeds
Filia, Anastasia (author)
Academy of Athens
Harland, Mark (author)
University of Leeds
Gascoyne, Joanne (author)
University of Leeds
Randerson-Moor, Juliette A. (author)
University of Leeds
Chan, May (author)
University of Leeds
Mell, Tracey (author)
University of Leeds
Jonsson, Goran (author)
Lund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Melanoma Genomics,Lund Melanoma Study Group,Lund University Research Groups
Timothy Bishop, D. (author)
University of Leeds
Newton-Bishop, Julia (author)
University of Leeds
Barrett, Jennifer H. (author)
University of Leeds
Nsengimana, Jeremie (author)
University of Leeds
show less...
 (creator_code:org_t)
2019
2019
English 12 s.
In: Clinical Cancer Research. - 1078-0432. ; 25:24, s. 7424-7435
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Purpose: Previously identified transcriptomic signatures have been based on primary and metastatic melanomas with relatively few American Joint Committee on Cancer (AJCC) stage I tumors, given difficulties in sampling small tumors. The advent of adjuvant therapies has highlighted the need for better prognostic and predictive biomarkers, especially for AJCC stage I and stage II disease. Experimental Design: A total of 687 primary melanoma transcriptomes were generated from the Leeds Melanoma Cohort (LMC). The prognostic value of existing signatures across all the AJCC stages was tested. Unsupervised clustering was performed, and the prognostic value of the resultant signature was compared with that of sentinel node biopsy (SNB) and tested as a biomarker in three published immunotherapy datasets. Results: Previous Lund and The Cancer Genome Atlas signatures predicted outcome in the LMC dataset (P = 10¯8 to 10¯4) but showed a significant interaction with AJCC stage (P = 0.04) and did not predict outcome in stage I tumors (P = 0.3–0.7). Consensus-based classification of the LMC dataset identified six classes that predicted outcome, notably in stage I disease. LMC class was a similar indicator of prognosis when compared with SNB, and it added prognostic value to the genes reported by Gerami and colleagues. One particular LMC class consistently predicted poor outcome in patients receiving immunotherapy in two of three tested datasets. Biological characterization of this class revealed high JUN and AXL expression and evidence of epithelial-to-mesenchymal transition. Conclusions: A transcriptomic signature of primary melanoma was identified with prognostic value, including in stage I melanoma and in patients undergoing immunotherapy.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view